Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 340

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 340
---
 of abnormal blood vessels.

| 177 |

Anti-VEGF drugs work to halt the
progression of neovascularization and require frequent and long-term injections directly into the eye. Whereas anti-VEGF therapy is effective
at slowing the progression of the disease, it does not address the underlying root cause (i.e. a blood clot in one or more of the retinal
veins). As a result, there continues to be a progressive, long-term deterioration of vision in most RVO patients.

To address this
treatment gap, we have developed a new approach to the treatment of RVO called Reflow RVO that is designed to treat the root
cause of the disease — namely the venous clot. The therapy combines intravenous administration of microspheres with non-invasive
therapeutic ultrasound delivered across the closed inferior eyelid. The microspheres have a diameter ranging between 1.1 to 3.3 microns
and are sufficiently small enough to pass through retinal vein occlusions. The ultrasound is administered through a proprietary ultrasound
device that has been designed specifically for the treatment of RVO in either out-patient retinal clinics or ambulatory surgical centers.
When the microspheres travel through the circulatory system and pass through the path of the ultrasound beam, they undergo multiples cycles
of expansion and contraction (cavitation). This cavitational process results in a focused release of energy in the vicinity of the blood
clot to non-invasively restore blood flow in the occluded vein. By treating the root cause of the disease, we believe this therapy has
the potential to significantly reduce the need for long-term anti-VEGF maintenance therapy and improve the quality of life for patients
inflicted by RVO.

Reflow RVOTM Product Components

A pre-clinical study has been completed that evaluated the feasibility of this therapeutic treatment regimen
in a rabbit model of BRVO. In this pre-clinical study, Rose Bengal-mediated laser-induced photothrombosis was used to induce an occlusion
in the branch retinal vein of all animals. Fluorescein angiography confirmed the occlusion on the day of the experiments and was used
for follow-up comparison. The active treatment group (n = 16) received a continuous intravenous infusion of microspheres and therapeutic
ultrasound for 30 minutes. Control groups received either therapeutic ultrasound plus intravenous saline infusion (n = 6) or no treatment
(n = 6).